Treatment of Confirmed Onychomycosis
Oral terbinafine 250 mg daily should be your first-line treatment for confirmed onychomycosis: 6 weeks for fingernails and 12-16 weeks for toenails. 1
First-Line Systemic Therapy
Terbinafine is superior to all other oral antifungals based on the highest quality evidence. In a large multicenter randomized trial of 508 patients, terbinafine achieved complete cure (mycological clearance plus normal-appearing nail) in 55% of patients versus only 26% with pulsed itraconazole at 72 weeks. More importantly, at 5-year follow-up, mycological cure without retreatment was maintained in 46% of terbinafine-treated patients versus only 13% with itraconazole. Relapse rates were dramatically lower with terbinafine (23% clinical, 21% mycological) compared to itraconazole (53% clinical, 48% mycological). 1
Dosing specifics:
- Toenails: 250 mg daily for 12-16 weeks
- Fingernails: 250 mg daily for 6 weeks
- Re-evaluate at 3-6 months and retreat if disease persists 1
Monitoring Requirements
Obtain baseline liver function tests and complete blood count in patients with:
- History of heavy alcohol consumption
- Known hepatitis or liver disease
- Haematological abnormalities
- Children (terbinafine is unlicensed in pediatrics) 1
Critical safety warning: Warn patients about permanent taste disturbance—though rare, this can be irreversible. 1
Second-Line Systemic Therapy
If terbinafine is contraindicated (active/chronic liver disease) or not tolerated, use itraconazole 1:
Continuous dosing: 200 mg daily for 12 weeks
Pulse dosing (preferred): 400 mg daily for 1 week per month
- 2 pulses for fingernails
- 3 pulses for toenails
Important: Itraconazole requires food and acidic pH for optimal absorption. Monitor liver function in patients on continuous therapy >1 month or with pre-existing hepatic dysfunction. 1
Third-Line Systemic Option
Fluconazole (off-label, not FDA-approved for onychomycosis but commonly used):
- 450 mg weekly for 3 months (fingernails) or ≥6 months (toenails)
- Mycological cure rates: 47-62% (toenails), 89-100% (fingernails)
- Consider when terbinafine and itraconazole are contraindicated
- Advantage: Once-weekly dosing improves compliance
- Disadvantage: Lower efficacy than terbinafine or itraconazole 1
Topical Therapy
Topical agents are less effective than oral therapy but appropriate for:
- Mild to moderate disease without matrix involvement
- Patients refusing or unable to take oral medications
- Combination therapy with oral agents (increases cure rates) 1, 2
FDA-Approved Topical Options (in order of efficacy):
Efinaconazole 10% solution (highest efficacy):
- Complete cure: RR 3.54 vs vehicle (high-quality evidence)
- Apply daily for 48 weeks
- Slight increase in adverse events (dermatitis, vesicles): RR 1.10 3, 2
Tavaborole 5% solution:
- Complete cure: RR 7.40 vs vehicle (moderate-quality evidence)
- Apply daily for 48 weeks
- Higher risk of application site reactions: RR 3.82 2
Ciclopirox 8% lacquer:
- Complete cure: RR 9.29 vs vehicle (low-quality evidence)
- Apply once or twice weekly for 6-12 months
- May cause application reactions, rashes, nail alterations 1, 2
Amorolfine 5% lacquer (approved in Europe, not US):
- Apply once or twice weekly for 6-12 months
- Adverse effects rare 1
Critical Practice Points
Always confirm diagnosis before treatment. Use potassium hydroxide preparation with microscopy, fungal culture, periodic acid-Schiff stain, or PCR. Never treat based on clinical appearance alone—therapy is lengthy, expensive, and has potential adverse effects. 4, 5
Combination therapy is superior to monotherapy. When response to topical therapy alone is likely poor, combine oral and topical agents. 1
Nail debridement improves outcomes. Mechanical removal of infected keratin reduces fungal load and enhances drug penetration. Use this concurrently with pharmacologic therapy. 5, 6
Set realistic expectations. Even with optimal treatment:
- Complete cure rates remain relatively low (55% at best with terbinafine)
- Toenail regrowth takes 12-18 months
- Recurrence rates approach 25% 4, 5
Device-Based Therapies
1064-nm Nd:YAG laser: Evidence is insufficient. We are uncertain whether it improves mycological cure (RR 1.04, very low-quality evidence). Complete cure was not measured in available studies. Not recommended as primary therapy. 2
Common Pitfalls to Avoid
- Don't skip confirmatory testing—other nail diseases mimic onychomycosis
- Don't use griseofulvin—it has lower efficacy and higher relapse rates than terbinafine/itraconazole 1
- Don't forget drug interactions with itraconazole (strong CYP450 inhibitor); terbinafine has minimal interactions except with CYP450 2D6 substrates 1
- Don't ignore contraindications—avoid terbinafine in active/chronic liver disease 1
- Don't expect immediate results—re-evaluate at 3-6 months, not earlier 1
Recurrence Prevention
After successful treatment, counsel patients on: